- Trials with a EudraCT protocol (7)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
7 result(s) found for: cidp.
Displaying page 1 of 1.
EudraCT Number: 2017-002511-34 | Sponsor Protocol Number: V1.0.14062017 | Start Date*: 2018-09-26 |
Sponsor Name:Academisch Medisch Centrum | ||
Full Title: Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in CIDP (OPTIC trial) | ||
Medical condition: Chronic inflammatory demyelinating polyneuropathy (CIDP) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2016-002411-17 | Sponsor Protocol Number: CIDP01 | Start Date*: 2019-04-29 | |||||||||||
Sponsor Name:UCB Biopharma SRL | |||||||||||||
Full Title: A Multicenter, Randomized, Subject-Blind, Investigator-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of Rozanolixizumab in Subjects with Chronic ... | |||||||||||||
Medical condition: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DK (Completed) NL (Completed) DE (Completed) ES (Completed) FR (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004392-12 | Sponsor Protocol Number: CIDP04 | Start Date*: 2019-11-20 | |||||||||||
Sponsor Name:UCB Biopharma SPRL | |||||||||||||
Full Title: An Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | |||||||||||||
Medical condition: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) FR (Completed) BE (Completed) ES (Restarted) NL (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005496-87 | Sponsor Protocol Number: 161403 | Start Date*: 2015-10-15 | |||||||||||
Sponsor Name:Baxalta Innovations GmbH | |||||||||||||
Full Title: A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (HYQVIA/HyQvia) and Immune Globulin Infusion (Human... | |||||||||||||
Medical condition: Chronic inflammatory demyelinating polyradiculoneuropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) DK (Completed) DE (Completed) SE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) NO (Completed) SK (Completed) GR (Completed) AT (Completed) PL (Completed) HR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000374-37 | Sponsor Protocol Number: 161505 | Start Date*: 2016-10-28 | |||||||||||
Sponsor Name:Baxalta Innovations GmbH | |||||||||||||
Full Title: Long-Term Tolerability and Safety of Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (HYQVIA/HyQvia) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculone... | |||||||||||||
Medical condition: Chronic inflammatory demyelinating polyradiculoneuropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DK (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) NO (Completed) GR (Completed) SK (Prematurely Ended) DE (Completed) PL (Completed) HR (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003076-39 | Sponsor Protocol Number: ARGX-113-1802 | Start Date*: 2020-06-25 | |||||||||||
Sponsor Name:argenx BVBA | |||||||||||||
Full Title: A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | |||||||||||||
Medical condition: Chronic Inflammatory Demyelinating Polyneuropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) PL (Completed) HU (Completed) ES (Completed) LV (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) BE (Completed) NL (Completed) BG (Completed) DK (Completed) AT (Completed) IT (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003107-35 | Sponsor Protocol Number: ARGX-113-1902 | Start Date*: 2020-07-15 | |||||||||||
Sponsor Name:argenx BVBA | |||||||||||||
Full Title: Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuro... | |||||||||||||
Medical condition: Chronic Inflammatory Demyelinating Polyneuropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) CZ (Completed) BE (Trial now transitioned) HU (Completed) PL (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Trial now transitioned) ES (Trial now transitioned) BG (Trial now transitioned) DK (Trial now transitioned) AT (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
